Drug Trial Radar · NCT00483106
Clinical and Pharmacogenetic Study of Attention Deficit With Hyperactivity Disorder (ADHD)
Last checked: Nov 19, 2026Latest source record: Mar 16, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
885
Actual
Start
Nov 1999
Primary completion
Mar 31, 2020
Study completion Mar 31, 2020
Sponsor
- Lead sponsor
- McGill UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 6, 2007
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Basic science
- Who can join
- All sexes, from 6 years, up to 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Attention deficit with hyperactivity disorder (ADHD) is a very common behavioral problem during childhood. It is estimated that up to 80% of this disorder could be related to genetic factors. The most common treatment for ADHD is psychostimulants. In this study, the researchers investigate the effect of genetic variants in increasing the risk for behaviours pertinent to ADHD or in modulating the response of these behaviours to methylphenidate. Response to methylphenidate is evaluated through a double blind placebo controlled one week study.
Conditions
- Attention Deficit Hyperactivity Disorder
Interventions
RitalinDrug
0.25 mg/kg bid, orally for 7 consecutive days
PlaceboDrug
taken orally twice a day for 7 consecutive days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Conners' Global Index - Parent Version (CGI-P)Time frame: Once weekly during the medication trial
- Conner's Global Index - Teacher Version (CGI-T)Time frame: Once weekly during the medication trial
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Douglas Mental Health University Institute
Montreal, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.